About Sail:
Sail Biomedicines is harnessing evolutionary and artificial intelligence to revolutionize programmable medicines. Sail’s platform combines first-in-class programmable RNA technology (Endless RNATM or eRNA), and an industry-leading platform of programmable nanoparticles, utilizing natural components, to unlock comprehensive programming of medicines for the first time. By leveraging cutting-edge eRNA and nanoparticle deployment technology, Sail is building a wealth of data, enabling unparalleled use of AI techniques to identify and design fully programmable medicines that are potent, targeted, versatile, and tunable. Sail was founded by Flagship Pioneering.
The Role:
Sail Biomedicines is seeking a highly motivated Scientist I/II to join our mission of developing novel programmable delivery technology. This is a unique opportunity to be an integral part of a team dedicated to creating a transformative delivery platform for precision targeting of therapeutics. Your contributions will play a crucial role in testing and further training advanced AI/ML models. This position offers the chance to excel in your field of expertise while also collaborating with multiple teams across the company. This lab-based onsite position requires the majority of time to be dedicated to hands-on lab work, focusing on experimental tasks and collaboration within the team to drive project success.
Responsibilities:
- Design and optimize novel formulations for nucleic acid (mRNA, siRNA, DNA, etc.) delivery, while providing critical input on our overall formulation strategy
- Develop and validate analytical methods for cargo and formulations
- Execute experiments that will serve as the basis for the company’s ongoing platform and intellectual property development
- Develop novel methods to help advance our understanding of nanoparticle mechanism of action, evaluating functionality, targeting efficiency and potency of novel delivery modalities
- Work closely with cross-functional teams across Sail, collaborators, and CROs to progress candidates from discovery through IND-enabling studies.
- Manage multiple experiments, projects, and interactions with supporting functions simultaneously
- Interpret, troubleshoot, and report complex data
Minimum qualifications:
- PhD. in Pharmaceutical Science, Chemical Engineering, Biological Engineering, Chemistry, or related discipline, with a demonstrated strong background in developing diverse formulations with in vitro/in vivo applications
- Execution-focused, team-oriented, and highly motivated, with strong work ethic Ability to work independently, manage multiple projects concurrently, and collaborate across disciplines
- Strong verbal, written communication, and problem-solving skills
- Ability to excel in a fast-paced, dynamic, innovative environment
Strongly preferred qualifications:
- Experience with in vivo delivery of nucleic acids
- Strong disposition for physicochemical and biophysical analytics, including assay development
- Proficiency in analytical techniques such as differential scanning calorimetry (DSC), TGA, SANS, SAXS, FTIR, HPLC, DSC, Mass spectrometry, DLS, zeta potential, UV-Vis, and fluorescence spectrophotometry, etc. is preferred
Sail Biomedicines is an Equal Opportunity Employer. Sail does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, national origin, veteran status, or any other status protected under federal, state, or local law.
Top Skills
What We Do
Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells – both within the cell (mRNA), and, remarkably, to the cell - using what surrounds it. The trillions of non-human cells in the human ecosystem have evolved natural nanoparticles that precisely shuttle biomolecules into human cells, providing the missing pieces to fully unlock programmable medicines. Senda’s proprietary platform includes the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life – accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines. The unique properties of these medicines create new frontiers for mRNA therapeutics and vaccines for infectious, genetic, autoimmune, and metabolic diseases and oncology indications – with further potential to transform the gene editing and protein-based therapy landscapes as well. Based in Cambridge, MA, Senda was founded by Flagship Pioneering.
